Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511238 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 312
- Enrollment target
NCT00511238 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 312 participants.
The verdict
NCT00511238, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 312 participants
- Enrollment target
Study Summary
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma. Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.
Interventions
- DRUG carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511238
The ClinicalTrials.gov registry entry for NCT00511238 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which carfilzomib is the first listed.
NCT00511238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511238 about?
NCT00511238 is a clinical study titled "Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma". To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma. Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.
What is the current status of trial NCT00511238?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 312 participants. The study started on 2007-08. Estimated completion is 2012-10.
What interventions are being tested in trial NCT00511238?
The interventions under investigation include: carfilzomib (DRUG).
Who is sponsoring clinical trial NCT00511238?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.